Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver

SK Geevarghese, DA Geller, HA de Haan… - Human gene …, 2010 - liebertpub.com
This multicenter phase I/II study evaluated the safety, pharmacokinetics, and antitumor
effects of repeated doses of NV1020, a genetically engineered oncolytic herpes simplex …

Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor …

I Zlobec, K Baker, P Minoo, JR Jass, L Terracciano… - Clinical cancer …, 2008 - AACR
Purpose: To identify independent clinicopathologic factors and protein markers leading to
the identification of colorectal cancer (CRC) patients with mismatch repair proficiency at risk …

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

OA Khan, M Ranson, M Michael, I Olver… - British journal of …, 2008 - nature.com
To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5
consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients …

[HTML][HTML] Determining the survival rate of colorectal cancer in Iran: A systematic review and meta-analysis

B Tahmasbi, G Abedi, M Moosazadeh… - Asian Pacific journal …, 2018 - ncbi.nlm.nih.gov
Objective: Colorectal cancer is one of the most common causes of death in the world.
Despite of remarkable advances in medical sciences, cancer is an important disease and …

[HTML][HTML] Legal & ethical dilemmas in incidental findings during surgery

SK Sarker - International Journal of Surgery, 2020 - Elsevier
Background Discovering IF (incidental findings) during surgery results in ethical and legal
dilemmas for the surgeon, especially those in training or recently qualified. The situation is …

Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports

A Langerak, G River, E Mitchell, P Cheema… - Clinical colorectal …, 2009 - Elsevier
Purpose Monoclonal antibodies against the epidermal growth factor receptor approved for
treating metastatic colorectal cancer (mCRC) include cetuximab (a chimeric antibody) and …

Effects of miR-489 targeting on SOX4 gene on proliferation and apoptosis of human hepatocellular carcinoma cells

B Wang, WX Jin, YL Zhang, L Huang, HB Ni… - African health …, 2020 - ajol.info
Background: Hepatocellular carcinoma is one of the most common malignant tumors found
all over the globe. Despite advances in surgery and chemotherapy, the five-year survival …

Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma

S De Dosso, L Mazzucchelli, M Ghielmini… - Tumori …, 2009 - journals.sagepub.com
Esophageal localization of adenoid cystic carcinoma of minor salivary glands is rare; it may
occur in the early to mid-sixties' age group and is more frequently encountered in men than …

Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers

D Mischek, R Steinborn, H Petznek… - BioMed Research …, 2009 - Wiley Online Library
To develop and evaluate new therapeutic strategies for the treatment of human cancers, well‐
characterised preclinical model systems are a prerequisite. To this aim, we have established …

[HTML][HTML] 结肠癌组织中miR-155 表达在预测复发转移中的价值及其与血清CEA 的相关性

黄少军, 汪晶晶, 江华, 曹红亮 - 肿瘤防治研究, 2014 - zlfzyj.com
目的分析结肠癌组织中miR-155 表达与血清CEA 的相关性, 探讨miR-155
表达在预测复发转移中的价值. 方法收集84 例结肠癌标本及对应的癌旁组织 …